臨床外科62巻7号

2007年07月発行

特集 乳癌の治療戦略―エビデンスとガイドラインの使い方

再発乳癌に対する化学療法

著者： 稲治英生¹

所属機関： ¹地方独立行政法人大阪府立病院機構大阪府立成人病センター乳腺・内分泌外科

ページ範囲：P.917 - P.922

文献概要

要旨：乳癌は再発後も化学療法などの薬物療法が奏効することが多く，再発後も長期生存が期待できる．しかし，術後補助療法の場合と異なり，化学療法によって治癒が得られるわけではなく，たえずquality of life（QOL）とのバランスを考慮した治療法選択が求められる．また，周術期薬物療法の内容や再発の部位・腫瘍量，患者のperformans status（PS）などによっても微妙に異なるので，必ずしもエビデンスに基づいた治療がアルゴリズムどおり行えるとは限らない．そこに再発乳癌治療の難しさがある．

参考文献

1）Hortobagyi GN：Treatment of breast cancer. N Engl J Med 339：974-984, 1998

2）Piccart MJ, Awada A, Hamilton A：Integration of new therapies into management of metastatic breast cancer：a focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. ASCO Educational Book. ASCO, 1999, pp526-539

3）National Comprehensive Cancer Network：Clinical Practice Guidelines in Oncology. v. 1. 2007（http://www.nccn.org）

4）日本乳癌学会（編）：科学的根拠に基づく乳癌診療ガイドライン　1．薬物療法．金原出版，2004

5）Cleator S, Heller W, Coombes RC：Triple-negative breast cancer：therapeutic options. Lancet Oncol 8：235-244, 2007

6）Gehrsi D, Wilcken N, Simes RJ：A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93：293-301, 2005

7）Sledge GW, Neuberg D, Bernardo P, et al：PhaseⅢ trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer：an intergroup trial（E1193）. J Clin Oncol 21：588-592, 2003

8）Jones SE, Erban J, Overmoyer B, et al：Randomized phaseⅢ study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23：5542-5551, 2005

9）岩田広治，佐伯俊昭：乳がん薬物療法の現状．乳癌の臨 21：311-322，2006

10）Zelek L, Barthier S, Riofrio M, et al：Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92：2267-2272, 2001

11）Burstein HJ, Kuter I, Campos SM, et al：Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19：2722-2730, 2001

12）Blum JL, Dees EC, Chacko A, et al：PhaseⅡ trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24：4384-4390, 2006

13）O'Shaughnessy J, Miles D, Vukelja S, et al：Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer：phase Ⅲ trial results. J Clin Oncol 20：2812-2823, 2002

14）Saeki T, Takashima S, Sano M, et al：A phaseⅡ study of S-1 in patients with metastatic breast cancer―a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11：194-202, 2004

15）Sato A, Kubota T, Fukushima M, et al：Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplant into SCID mice. Oncol Rep 15：1517-1522, 2006

16）Slamon DJ, Leyland-Jones B, Shak S, et al：Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344：783-792, 2001

17）Marty M, Cognetti F, Maraninchi D, et al：Randomized phaseⅡ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment：the M77001 study group. J Clin Oncol 23：4265-4274, 2005

18）Geyer CE, Forster J, Lindquist D, et al：Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355：2733-2743, 2006